Abstract: Mucus-penetrating liposomal nanoparticles and methods of making and using thereof are described herein. The nanoparticles contain one or more lipids, one or more PEG-conjugated lipids, and optionally one or more additional materials that physically and/or chemically stabilize the particles. The nanoparticle have an average diameter of about 100 nm to about 300 nm, preferably from about 100 nm to about 250 nm, more preferably from about 100 nm to about 200 nm. The particles are mobile in mucus. The liposomes can further contain one or more therapeutic, prophylactic, and/or diagnostic agent to be delivered to a mucosal surface, such as the CV tract, the colon, the nose, the lungs, and/or the eyes. The liposomes can further contain one or more CEST agents to allow real time imaging of the particles in a live animal. The particles may also further contain an imaging agent, such as a fluorescent label.
Type:
Grant
Filed:
May 6, 2013
Date of Patent:
February 13, 2018
Assignee:
The Johns Hopkins University
Inventors:
Justin Hanes, Kannie Wai Yan Chan, Michael T. McMahon, Ming Yang, Tao Yu
Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
January 23, 2018
Assignees:
Emory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
Inventors:
Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
Abstract: An object of the present invention is to provide a drug delivery system capable of sustainedly releasing a drug noninvasively at any given point in time. The present invention relates to a liposome complex comprising a liposome membrane-constituting substance bonded to a light-absorbing compound having an absorption wavelength in the near-infrared region, selected from the group consisting of indocyanine green dyes, phthalocyanine dyes, squarylium dyes, croconium dyes, and diimmonium dyes.
Type:
Grant
Filed:
October 3, 2012
Date of Patent:
January 23, 2018
Assignees:
National University Corporation Tottori University, National University Corporation Chiba University
Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.
Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.
Abstract: Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.
Type:
Grant
Filed:
November 8, 2012
Date of Patent:
December 26, 2017
Assignee:
The Board of Trustees of the University of Arkansas
Inventors:
Daniel Fologea, Ralph Henry, Greg Salamo, Yuriy Mazur, Michael J. Borrelli
Abstract: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.
Type:
Grant
Filed:
April 11, 2012
Date of Patent:
December 12, 2017
Assignee:
Biolipox AB
Inventors:
Lena Pereswetoff-Morath, Anders Carlsson
Abstract: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.
Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.
Type:
Grant
Filed:
June 30, 2014
Date of Patent:
November 28, 2017
Assignee:
INSMED INCORPORATED
Inventors:
Lawrence T. Boni, Brian S. Miller, Vladimir Malinin, Xingong Li
Abstract: The present invention provides novel liposomal formulations of polymyxin B and pharmaceutical compositions thereof useful for the treatment of bacterial infections. The liposomal formulation comprises a lipid component formed as vesicles each having a minimum size of at least 500 nm and polymyxin B encapsulated in the vesicles. The present invention also provides a drug delivery system that comprises a plurality of liposomes encapsulating a polymyxin B therein, where the liposomes have a minimum vesicular size of at least 500 nm. The liposomes comprising the drug delivery system are useful to increase efficacy of a treatment for a bacterial infection by increasing bioavailability and distribution of the polymyxin B within the subject.
Abstract: We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
November 14, 2017
Inventors:
Susan T. Laing, Shaoling Huang, David D. McPherson, Christy K. Holland, Melvin E. Klegerman
Abstract: The invention provides pharmaceutical compositions containing a vehicle for the targeted delivery of therapeutic and diagnostic agents for the treatment of hyperproliferative diseases. The targeting component of the vehicle is a cystine molecule that is coupled to the cargo component, which can be either a therapeutic or diagnostic agent or to a nanoparticle composition that contains the therapeutic agent or diagnostic. The invention also provides methods of treating hyperproliferative disorders by targeting hyperproliferative disease cells for the targeted delivery of a therapeutic or diagnostic agent.
Type:
Grant
Filed:
September 10, 2012
Date of Patent:
November 7, 2017
Assignee:
WESTERN UNIVERSITY OF HEALTH SCIENCES
Inventors:
Maria Polikandritou Lambros, Ying Huang, Hari Chandana Mulamalla
Abstract: Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed.
Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
Type:
Grant
Filed:
October 28, 2010
Date of Patent:
September 26, 2017
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Lois Gibson, William Lambert, Benjamin W. Li, Liangjin Zhu
Abstract: The present invention relates to the topical and oral delivery of a composition comprising one or more active agents for treating a disease or symptoms in a subject. In some embodiments, the present invention comprises a composition comprising at least one active compound, e.g., finasteride or minoxidil, and one or more lipids. In some embodiments, the present invention relates to composition and method of preparation for treating androgenic alopecia (AGA), prevention of hair loss and female hirsutism. In some embodiment, the present invention comprises finasteride and at least one lipid component for the treatment of benign prostatic hyperplasia. In some embodiment, the present invention comprises tacrolimus or amphotericin B and at least one lipid component for the treatment of skin or eye related diseases.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
September 5, 2017
Assignee:
JINA PHARMACEUTICALS, INC.
Inventors:
Shoukath M. Ali, Ateeq Ahmad, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
Abstract: Compositions comprising therapeutically effective amounts of lamellar bodies to restore lubricity and non-stick properties to mucous surfaces for conditions characterized by dry adherent surfaces, particularly those surfaces close to the body openings and conditions of the eye.
Abstract: A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury in tissue at risk of such injury, such as heart and brain tissue.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
August 22, 2017
Assignees:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE JOHNS HOPKINS UNIVERSITY
Inventors:
Corinne Bright, Rachel Bright, Eric Churchill, Kam W. Leong, Daria Mochly-Rosen
Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.
Abstract: Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.
Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
Type:
Grant
Filed:
July 21, 2016
Date of Patent:
August 22, 2017
Assignee:
ZONEONE PHARMA, INC.
Inventors:
Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.